TY - JOUR
T1 - Intensive lifestyle modifications with or without liraglutide 3mg vs sleeve gastrectomy
T2 - A three-arm non-randomized, controlled, pilot study
AU - Capristo, Esmeralda
AU - Panunzi, Simona
AU - De Gaetano, Andrea
AU - Raffaelli, Marco
AU - Guidone, Caterina
AU - Iaconelli, Amerigo
AU - L’Abbate, Luca
AU - Birkenfeld, Andreas L.
AU - Bellantone, Rocco
AU - Bornstein, Stefan
AU - Mingrone, Geltrude
PY - 2017/12/29
Y1 - 2017/12/29
N2 - Background/Objectives As only 1% of clinically eligible subjects choose to undergo surgical treatment for obesity, other options should be investigated. This study aimed to assess the effects of intensive lifestyle modification (ILM) with or without 3-mg liraglutide daily vs sleeve gastrectomy (SG) on BMI after 1 year. Subjects/Methods In this study performed at an Italian university hospital, non-diabetic patients eligible for bariatric surgery were recruited from a weight-loss clinic and had the option to choose from three possible weight-loss programmes up to an allocation of 25 subjects in each arm matched by BMI and age. ILM consisted in 813 kcal of a very low-calorie diet (VLCD) for 1 month, followed by a diet of 12 kcal/kg body weight of high protein and high fat for 11 months plus 30 min of brisk walking daily and at least 3 h of aerobic exercise weekly. SG patients followed a VLCD for 1 month and a free diet thereafter. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months. Results A total of 75 patients were enrolled; retention was 100% in the SG and 85% in the two medical arms. SG reduced BMI by 32% (P < 0.001 vs medical arm), while ILM + liraglutide and ILM led to BMI reductions of 24% and 14%, respectively (P < 0.001). More women allocated themselves to the ILM + liraglutide group. Weight loss was 43 kg with SG, 26 kg with ILM + liraglutide and 15 kg with ILM alone. Lean body mass reductions were − 11.6 kg with SG, − 6.3 kg with ILM and − 8.3 kg with ILM + liraglutide. Prevalence of prediabetes was significantly lower with ILM + liraglutide, and insulin resistance was reduced by about 70% by both ILM + liraglutide and SG vs 39% by ILM alone. Cardiometabolic risk factors were greatly reduced in all three groups. Discussion At least in the short-term, liraglutide 3.0 mg once daily associated with drastic calorie-intake restriction and intensive physical activity promoted a 24% weight loss, which was almost two times greater than ILM alone and only about 25% less than with SG, while preserving lean body mass. Although this study was non-randomized, it was designed to explore the efficacy of medical treatments for obesity in everyday clinical practice.
AB - Background/Objectives As only 1% of clinically eligible subjects choose to undergo surgical treatment for obesity, other options should be investigated. This study aimed to assess the effects of intensive lifestyle modification (ILM) with or without 3-mg liraglutide daily vs sleeve gastrectomy (SG) on BMI after 1 year. Subjects/Methods In this study performed at an Italian university hospital, non-diabetic patients eligible for bariatric surgery were recruited from a weight-loss clinic and had the option to choose from three possible weight-loss programmes up to an allocation of 25 subjects in each arm matched by BMI and age. ILM consisted in 813 kcal of a very low-calorie diet (VLCD) for 1 month, followed by a diet of 12 kcal/kg body weight of high protein and high fat for 11 months plus 30 min of brisk walking daily and at least 3 h of aerobic exercise weekly. SG patients followed a VLCD for 1 month and a free diet thereafter. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months. Results A total of 75 patients were enrolled; retention was 100% in the SG and 85% in the two medical arms. SG reduced BMI by 32% (P < 0.001 vs medical arm), while ILM + liraglutide and ILM led to BMI reductions of 24% and 14%, respectively (P < 0.001). More women allocated themselves to the ILM + liraglutide group. Weight loss was 43 kg with SG, 26 kg with ILM + liraglutide and 15 kg with ILM alone. Lean body mass reductions were − 11.6 kg with SG, − 6.3 kg with ILM and − 8.3 kg with ILM + liraglutide. Prevalence of prediabetes was significantly lower with ILM + liraglutide, and insulin resistance was reduced by about 70% by both ILM + liraglutide and SG vs 39% by ILM alone. Cardiometabolic risk factors were greatly reduced in all three groups. Discussion At least in the short-term, liraglutide 3.0 mg once daily associated with drastic calorie-intake restriction and intensive physical activity promoted a 24% weight loss, which was almost two times greater than ILM alone and only about 25% less than with SG, while preserving lean body mass. Although this study was non-randomized, it was designed to explore the efficacy of medical treatments for obesity in everyday clinical practice.
KW - Body composition
KW - Bariatric surgery
KW - Lifestyle modifications
KW - Liraglutide
KW - Obesity
KW - Very low-calorie diet
U2 - 10.1016/j.diabet.2017.12.007
DO - 10.1016/j.diabet.2017.12.007
M3 - Article
SN - 1262-3636
JO - DIABETES AND METABOLISM
JF - DIABETES AND METABOLISM
ER -